Lucid Diagnostics Inc. filings document a commercial-stage medical diagnostics issuer focused on esophageal precancer detection, its public-company governance, and its capital structure. Its 8-K reports disclose operating results and business updates for EsoGuard and EsoCheck, Regulation FD communications, completed common stock offerings, shelf registration statement references, proceeds for working capital and general corporate purposes, and related exhibits.
Proxy materials cover annual meeting matters, director elections, board classification, and stockholder voting. Other material-event filings address board appointments, non-employee director compensation arrangements, indemnification agreements, and governance rights associated with holders of the company’s convertible secured promissory notes due 2029.
Lucid Diagnostics Inc. reported first-quarter 2026 results and a business update centered on its EsoGuard esophageal DNA test. The company processed 3,177 EsoGuard tests and generated $1.3 million in EsoGuard revenue for the quarter.
GAAP net loss was approximately $13.9 million, or $(0.17) per common share, including a deemed Preferred Stock dividend that brought net loss attributable to common stockholders to about $23.6 million. Non-GAAP adjusted loss was roughly $10.5 million, or $(0.07) per share.
Lucid ended March 31, 2026 with $27.9 million in cash and cash equivalents and had recently completed an underwritten public offering of common stock, netting about $17 million, resulting in $45 million in proforma cash and a runway extending into 2027. Management emphasized progress toward Medicare coverage, growing EsoGuard demand, and broader engagement with health systems, the VA, and commercial payors.
Lucid Diagnostics Inc. reported higher Q1 2026 revenue but continued large losses and liquidity pressure. Revenue rose to about $1.3 million from $0.8 million a year earlier, driven by more EsoGuard test billings.
The net loss attributable to common stockholders was about $23.6 million versus $36.0 million in Q1 2025, or $(0.17) per share compared with $(0.52). Operating cash outflow was roughly $12.1 million, leaving cash of about $27.9 million and working capital near $2.0 million as of March 31, 2026.
Lucid carries $21.975 million face value of Senior Secured Convertible Notes, measured at a fair value of $25.2 million, and must maintain at least $5.0 million in available cash while they are significantly outstanding. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern without more revenue and capital.
To bolster liquidity, Lucid raised approximately $5.3 million net in Q1 2026 through its at-the-market equity program and, after quarter-end, about $16.8 million net from an April 2026 registered direct offering of 18,000,000 shares at $1.00 per share. The company is seeking Medicare coverage for EsoGuard, has a recent U.S. Department of Veterans Affairs contract, and obtained a waiver through August 22, 2026 on a potential default tied to not yet receiving a positive Medicare decision.
Lucid Diagnostics Inc. is asking stockholders to elect three Class B directors, approve a major increase in authorized common shares, and ratify CBIZ CPAs P.C. as auditor at its June 24, 2026 virtual annual meeting.
The Authorized Capital Proposal would raise authorized common stock from 300,000,000 to 400,000,000 shares. As of April 27, 2026, 195,253,423 common shares were outstanding and large additional blocks were reserved for options, preferred stock and convertible notes, so more authorized shares would support financings, equity awards and conversions but could dilute existing holders and be used in anti-takeover contexts. PAVmed, the parent company, plans to vote in favor of all proposals.
Lucid Diagnostics Inc. Chief Medical Officer Victoria Lee Tou-ho filed an amended Form 3 updating her equity holdings. She reports 650,000 shares of Common Stock, representing restricted stock granted under the company’s 2018 Equity Plan with specific future vesting dates.
The restricted stock comprises 200,000 shares granted on November 6, 2023 vesting November 6, 2026; 150,000 shares granted February 20, 2025 vesting May 20, 2028; and 300,000 shares granted February 20, 2026 vesting May 20, 2029, all subject to forfeiture if service requirements are not met. She also holds an employee stock option for 100,000 shares of Common Stock at an exercise price of $1.25 per share, expiring on February 22, 2034, with one-third already vested and the remainder vesting in equal quarterly installments through December 31, 2026.
Lucid Diagnostics Inc. closed an underwritten public offering of 18,000,000 shares of common stock at $1.00 per share, raising gross proceeds of approximately $18 million. Net proceeds are expected to be about $16.8 million after underwriting discounts and expenses.
The company plans to use the net proceeds for working capital and general corporate purposes, helping fund its commercial-stage cancer prevention diagnostics business. The offering was made under an effective shelf registration statement on Form S-3, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.
Lucid Diagnostics is offering 18,000,000 shares of common stock at $1.00 per share. The prospectus supplement states an underwriting discount of $0.06 per share and estimated net proceeds to the company of approximately $16.8 million after underwriting discounts and estimated offering expenses.
Following the offering the company reports 195,253,423 shares of common stock outstanding. The shares are listed on the Nasdaq Capital Market under the symbol LUCD. Officers and directors agreed to 45-day lock-ups after closing. The supplement discloses expected delivery on or about April 24, 2026.
Lucid Diagnostics Inc. is raising $18,000,000 through an underwritten public offering of 18,000,000 common shares at a public offering price of $1.00 per share. Underwriters will purchase the shares at $0.94 per share, reflecting a $0.06 per-share underwriting discount, and will be reimbursed for certain expenses up to $75,000.
The company expects the sale to close on or about April 24, 2026, subject to customary conditions, with Canaccord Genuity and BTIG acting as joint bookrunners. The offering is made from Lucid’s effective Form S-3 shelf registration, and a related press release notes that the company intends to use net proceeds for working capital and general corporate purposes.
Lucid Diagnostics Inc. is asking shareholders at its virtual Annual Meeting to elect three Class B directors, ratify CBIZ CPAs P.C. as independent auditors, and approve an amendment to increase authorized common stock by 100,000,000 shares (from 300,000,000 to 400,000,000).
The Board set the record date as April 27, 2026 and scheduled the meeting for June 24, 2026 at 11:00 a.m. Eastern as a webcast. The Board and parent PAVmed support the proposals; the amendment would permit the Board to issue additional shares without further stockholder approval.
Lucid Diagnostics Inc. reported initial share ownership for Chief Medical Officer Lee Victoria Tou-ho. The filing shows direct ownership of 650,000 shares of common stock, including restricted stock granted under the company’s 2018 Equity Plan that vests over several future dates and can be forfeited if service requirements are not met.
The restricted stock grants consist of 200,000 shares awarded November 6, 2023 vesting on November 6, 2026, 150,000 shares awarded February 20, 2025 vesting on May 20, 2028, and 300,000 shares awarded February 20, 2026 vesting on May 20, 2029, all subject to continued service.